| Ayokunle Osho, MD | |
|
557 Brookdale Dr, Statesville, NC 28677-4100 | |
| (704) 872-6122 | |
| Not Available |
| Full Name | Ayokunle Osho |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 557 Brookdale Dr, Statesville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548526825 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | A133328 (California) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 02206 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Iredell Memorial Hospital Inc | Statesville, NC | Hospital |
| Uch-memorial Health System | Colorado springs, CO | Hospital |
| San Luis Valley Health | Alamosa, CO | Hospital |
| Lake Norman Regional Medical Center | Mooresville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiology And Imaging Consultants, Pc | 1850298647 | 39 |
| Iredell Radiology Associates Pa | 8426063371 | 3 |
| Uchealth Imaging Services Llc | 5799021291 | 141 |
News Archive
Type 2 diabetes is a condition in which the body does not make sufficient insulin or the insulin it makes doesn't work sufficiently well to maintain a normal level of blood glucose and so the blood glucose rises.
The National Institutes of Health has selected Axel Nimmerjahn for a highly competitive EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant. Dr. Nimmerjahn is an Assistant Professor in the Waitt Advanced Biophotonics Center and holds the Richard Allan Barry Developmental Chair.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
A shared decision-making process would assist doctors and parents who are facing the extraordinarily complex, challenging and controversial choices presented when infants are born with genetic or anatomical anomalies in sexual development and are being considered for elective corrective surgery, a new research paper suggests.
Demonstrating its dedication to close the loop for diabetes management, Medtronic, Inc. today announced that the first patient has been enrolled as part of the ASPIRE study of the MiniMed Paradigm x54 System featuring Low Glucose Suspend automation. Low Glucose Suspend works by automatically suspending insulin delivery temporarily if blood glucose levels become too low as defined by the patient and his or her healthcare provider and is a feature available commercially in Medtronic's Paradigm® Veo™ System in more than 35 countries outside of United States.
› Verified 7 days ago
| Entity Name | Iredell Radiology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235197179 PECOS PAC ID: 8426063371 Enrollment ID: O20060214000104 |
News Archive
Type 2 diabetes is a condition in which the body does not make sufficient insulin or the insulin it makes doesn't work sufficiently well to maintain a normal level of blood glucose and so the blood glucose rises.
The National Institutes of Health has selected Axel Nimmerjahn for a highly competitive EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant. Dr. Nimmerjahn is an Assistant Professor in the Waitt Advanced Biophotonics Center and holds the Richard Allan Barry Developmental Chair.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
A shared decision-making process would assist doctors and parents who are facing the extraordinarily complex, challenging and controversial choices presented when infants are born with genetic or anatomical anomalies in sexual development and are being considered for elective corrective surgery, a new research paper suggests.
Demonstrating its dedication to close the loop for diabetes management, Medtronic, Inc. today announced that the first patient has been enrolled as part of the ASPIRE study of the MiniMed Paradigm x54 System featuring Low Glucose Suspend automation. Low Glucose Suspend works by automatically suspending insulin delivery temporarily if blood glucose levels become too low as defined by the patient and his or her healthcare provider and is a feature available commercially in Medtronic's Paradigm® Veo™ System in more than 35 countries outside of United States.
› Verified 7 days ago
| Entity Name | Radiology & Imaging Consultants, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598700825 PECOS PAC ID: 1850298647 Enrollment ID: O20230915001802 |
News Archive
Type 2 diabetes is a condition in which the body does not make sufficient insulin or the insulin it makes doesn't work sufficiently well to maintain a normal level of blood glucose and so the blood glucose rises.
The National Institutes of Health has selected Axel Nimmerjahn for a highly competitive EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant. Dr. Nimmerjahn is an Assistant Professor in the Waitt Advanced Biophotonics Center and holds the Richard Allan Barry Developmental Chair.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
A shared decision-making process would assist doctors and parents who are facing the extraordinarily complex, challenging and controversial choices presented when infants are born with genetic or anatomical anomalies in sexual development and are being considered for elective corrective surgery, a new research paper suggests.
Demonstrating its dedication to close the loop for diabetes management, Medtronic, Inc. today announced that the first patient has been enrolled as part of the ASPIRE study of the MiniMed Paradigm x54 System featuring Low Glucose Suspend automation. Low Glucose Suspend works by automatically suspending insulin delivery temporarily if blood glucose levels become too low as defined by the patient and his or her healthcare provider and is a feature available commercially in Medtronic's Paradigm® Veo™ System in more than 35 countries outside of United States.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ayokunle Osho, MD 548 Brookdale Dr, Statesville, NC 28677-4108 Ph: (704) 872-6122 | Ayokunle Osho, MD 557 Brookdale Dr, Statesville, NC 28677-4100 Ph: (704) 872-6122 |
News Archive
Type 2 diabetes is a condition in which the body does not make sufficient insulin or the insulin it makes doesn't work sufficiently well to maintain a normal level of blood glucose and so the blood glucose rises.
The National Institutes of Health has selected Axel Nimmerjahn for a highly competitive EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant. Dr. Nimmerjahn is an Assistant Professor in the Waitt Advanced Biophotonics Center and holds the Richard Allan Barry Developmental Chair.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.
A shared decision-making process would assist doctors and parents who are facing the extraordinarily complex, challenging and controversial choices presented when infants are born with genetic or anatomical anomalies in sexual development and are being considered for elective corrective surgery, a new research paper suggests.
Demonstrating its dedication to close the loop for diabetes management, Medtronic, Inc. today announced that the first patient has been enrolled as part of the ASPIRE study of the MiniMed Paradigm x54 System featuring Low Glucose Suspend automation. Low Glucose Suspend works by automatically suspending insulin delivery temporarily if blood glucose levels become too low as defined by the patient and his or her healthcare provider and is a feature available commercially in Medtronic's Paradigm® Veo™ System in more than 35 countries outside of United States.
› Verified 7 days ago
Glenn C Webster, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 557 Brookdale Dr, Statesville, NC 28677 Phone: 704-873-5661 | |
Mr. Michael Keith Farris, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 557 Brookdale Dr, Statesville, NC 28677 Phone: 336-716-2255 | |
Dr. Paul Matthew Michaud, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 108 History Ln, Statesville, NC 28677 Phone: 865-766-6870 | |
Dr. Shiv Shashikant Patel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 730 Hartness Rd, Statesville, NC 28677 Phone: 704-924-7808 Fax: 704-761-6986 | |
Gayla S Lowery, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 557 Brookdale Dr, Statesville, NC 28677 Phone: 704-878-4615 Fax: 704-878-7193 |